Elevation Oncology Announces $65M Series B Financing and Promotion of Founder Shawn M. Leland to Chief Executive Officer

NRG1 fusions, a (PDX) model challenge

With the advent of the ‘precision oncology’ movement, the success of biomarker-driven targeted therapies has fundamentally changed our approach to drug development and treatment selection.

Read More


The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with NRG1 rearrangements

Read More